VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Cytologically confirmed small cell lung cancer
• •* Locally advanced or metastatic disease
• •* Recurrent or progressive disease after first-line standard cytotoxic therapy
• •Measurable or evaluable disease
• •Brain metastasis allowed
• •PATIENT CHARACTERISTICS:
• •ECOG performance status 0-2
• •Life expectancy ≥ 2 months
• •Granulocyte count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Creatinine ≤ 2.0 mg/dL
• •Bilirubin ≤ 2.5 mg/dL
• •AST and ALT ≤ 3 times upper limit of normal (ULN) (5 times ULN if liver metastases present)
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No active uncontrolled bleeding
• •No active infection
• •Must not require supplemental oxygen at rest
• •No active heart disease
• •No myocardial infarction within the past 3 months
• •No uncontrolled congestive heart failure
• •No uncontrolled arrhythmias
• •No uncontrolled coronary artery disease
• •PRIOR CONCURRENT THERAPY:
• •See Disease Characteristics
• •More than 3 weeks since prior radiotherapy, biologic therapy or chemotherapy (6 weeks for nitrosoureas or mitomycin C)
• •* Prior radiotherapy within the past 3 weeks allowed if exposure involves no more than 30% of bones with significant bone marrow-producing capabilities (e.g., vertebral bodies and long bones)
• •At least 2 weeks since prior surgery or hormonal therapy
• •Must not require any immediate palliative treatment including surgery
• •Must have recovered from prior anticancer therapy
• •* Persistent, stable chronic toxic effects ≤ grade 1 are allowed
• •No more than 1 prior systemic chemotherapy regimen for locally advanced or metastatic disease
• •No other concurrent anticancer therapy
• •No other concurrent investigational agent
• •No concurrent disulfiram